Do Topical Corticosteroids or Calcineurin Inhibitors Improve Repigmentation with 308 nm Excimer Therapy?

What a 2026 network meta-analysis reveals about combination treatment for vitiligo.

Adding a topical medication to 308 nm excimer phototherapy is one way clinicians approach vitiligo treatment. Two options—topical calcineurin inhibitors and topical corticosteroids—have been studied in combination with targeted light. The question is whether these combinations improve repigmentation compared with excimer treatment alone, and whether the advantage holds when different treatment outcomes are considered.

A systematic review and network meta-analysis published in Pigment Cell & Melanoma Research in January 2026 examined combination treatments across randomized trials involving 1,841 participants. The authors compared excimer 308 nm light alone with several adjunctive approaches, including topical calcineurin inhibitors, topical corticosteroids, antioxidants and platelet-rich plasma (PRP). The primary outcomes were the proportions of patients achieving at least 50%, at least 75%, and 100% skin repigmentation. [1]

The results were not identical across these three thresholds. Topical calcineurin inhibitors and topical corticosteroids showed significant advantages over excimer monotherapy for at least 50% and complete repigmentation, but neither combination demonstrated a statistically significant advantage at the 75% threshold. That difference is central to interpreting the findings.

What the 2026 Review Compared

The review included randomized trials of excimer 308 nm light for vitiligo, covering both excimer laser and excimer lamp devices. The authors searched MEDLINE, Embase and the Cochrane Library through November 2024. The analysis therefore reflects the available evidence up to that date, rather than every study published through 2026. [1]

The trials varied in their patient populations, adjunctive treatments and treatment protocols. The authors used a network meta-analysis to combine direct and indirect comparisons across the available evidence.

This method can estimate relative effects when not every intervention has been compared directly with every other option. It does not mean that all combinations have been tested head to head, or that the resulting estimates establish a definitive ranking for clinical practice.

Topical Calcineurin Inhibitors: Results at Two Repigmentation Thresholds

For patients achieving at least 50% repigmentation, excimer 308 nm light combined with a topical calcineurin inhibitor had a risk ratio (RR) of 1.47 compared with excimer monotherapy (95% confidence interval [CI] 1.19–1.81). For complete repigmentation, the RR was 1.60 (95% CI 1.03–2.49). Both results were statistically significant. [1]

An RR of 1.47 represents a 47% higher relative probability of reaching the specified outcome compared with the monotherapy group. It does not mean that 47 additional patients out of every 100 achieved repigmentation. The absolute benefit depends on the response rate with monotherapy.

The complete-repigmentation estimate also warrants careful interpretation. Although statistically significant, its confidence interval is relatively wide, leaving uncertainty about the precise size of the benefit.

For clinicians considering 308 nm excimer calcineurin inhibitors as a combination approach, the findings support considering this option in appropriately selected patients. They do not establish a universal treatment protocol or predict an individual patient's response.

Topical Corticosteroids: A Similar Pattern, with Different Estimates

The analysis also found significant improvements when excimer 308 nm light was combined with topical corticosteroids.

For at least 50% repigmentation, the RR was 1.65 (95% CI 1.32–2.06) compared with excimer monotherapy. For complete repigmentation, the RR was 2.31 (95% CI 1.50–3.56). [1]

These results indicate a higher relative probability of reaching both outcomes in the combination group. They do not prove that topical corticosteroids outperform calcineurin inhibitors. Each estimate compares a combination with monotherapy; the difference between the two RRs is not itself evidence of superiority in a direct comparison.

The choice of topical corticosteroid also requires clinical judgement. Potency, duration, anatomical site and potential adverse effects all influence whether a particular regimen is appropriate.

Taken together, the results favour both topical approaches over excimer monotherapy for the two reported thresholds. They do not identify one preferred combination for every patient.

Why the 75% Repigmentation Result Matters

The evidence was less conclusive for patients achieving at least 75% repigmentation.

For excimer combined with topical calcineurin inhibitors, the RR was 2.38 (95% CI 0.91–6.23). For the topical corticosteroid combination, it was 1.16 (95% CI 0.41–3.26). Neither comparison reached statistical significance because both confidence intervals crossed 1. [1]

These estimates do not demonstrate that the combinations have no effect. Rather, the available evidence does not establish a statistically significant advantage at this threshold, and the wide confidence intervals leave considerable uncertainty.

The three outcomes should therefore remain distinct:

• At least 50% repigmentation: both topical combinations showed statistically significant improvements over monotherapy.

• At least 75% repigmentation: neither combination demonstrated a statistically significant advantage.

• Complete repigmentation: both combinations showed statistically significant improvements over monotherapy.

A favourable result at one threshold cannot automatically be extended to every measure of repigmentation. Reporting only the most favourable outcomes would leave out an important part of the evidence.

What About Other Combination Treatments?

The review also examined antioxidants, intramuscular corticosteroids and PRP.

For at least 50% repigmentation, excimer light combined with topical antioxidants had an RR of 43.00 (95% CI 2.68–688.68). The reported RRs were 1.76 for intramuscular corticosteroids (95% CI 1.13–2.74) and 1.76 for PRP (95% CI 1.32–2.35). [1]

The antioxidant estimate is particularly imprecise. Its exceptionally wide confidence interval means the point estimate should not be interpreted as evidence of a dramatically greater clinical benefit than other combinations.

The results for intramuscular corticosteroids and PRP also need to be considered in their specific clinical contexts. These findings do not establish that either intervention should routinely be added to excimer treatment for every patient.

For excimer monotherapy vs combination therapy, the topical calcineurin inhibitor and topical corticosteroid comparisons provide the clearest results in this review across both the 50% and complete-repigmentation thresholds. The other interventions broaden the range of approaches under investigation, but their estimates do not justify ranking all combinations by apparent effect size alone.

What the Evidence Cannot Tell Us

Several limitations affect how these findings should be applied in practice.

First, the literature search ended in November 2024. The review was published in 2026, but it does not include trials published after the search cutoff.

Second, the studies differed in patient populations, treatment schedules and outcome assessment. Network estimates depend on the quality and comparability of the available direct and indirect evidence.

Third, the analysis does not establish an optimal drug, application schedule, excimer treatment frequency or treatment duration for all patients. Nor does achieving a particular repigmentation threshold establish that the result will persist after treatment ends.

The findings are best understood as comparative evidence for selected treatment combinations, not as a universal protocol. Individual treatment decisions still require assessment of disease characteristics, previous treatment, anatomical site, contraindications and patient preferences.

Applying the Evidence to Targeted Phototherapy

For clinics using targeted 308 nm phototherapy, the review provides a useful basis for discussing combination treatment with patients. Topical calcineurin inhibitors and topical corticosteroids are options worth considering when clinically appropriate, but the expected benefit cannot be predicted from the pooled relative effects alone.

KernelMed's KN-5000D and KN-5000E belong to its 308 nm excimer product range. The review evaluated combination treatment across excimer devices; it did not establish device-specific clinical outcomes for either model.

Product information: https://www.kernelmedint.com/product-list/308nm-excimer-laser

Clinical Takeaway

The 2026 network meta-analysis supports considering topical calcineurin inhibitors or topical corticosteroids alongside 308 nm excimer therapy for appropriately selected patients. Both combinations improved the relative probability of achieving at least 50% and complete repigmentation compared with excimer monotherapy, while the results at the 75% threshold remained inconclusive.

The evidence supports these combinations as clinical options, not a single preferred regimen for all patients.

FAQ

Does combining 308 nm excimer therapy with topical treatment improve vitiligo repigmentation?

In the 2026 network meta-analysis, combinations with topical calcineurin inhibitors and topical corticosteroids significantly improved the relative probability of achieving at least 50% and complete repigmentation compared with excimer monotherapy. Neither combination showed a statistically significant advantage at the 75% threshold. [1]

Which topical treatments were evaluated with 308 nm excimer light?

The review examined several adjunctive approaches. Topical calcineurin inhibitors and topical corticosteroids were among the combinations with statistically significant results at the 50% and complete-repigmentation thresholds. The analysis did not establish one universally optimal combination.

Does a higher risk ratio mean more patients will achieve complete repigmentation?

Not necessarily in absolute terms. A risk ratio compares the relative probability of an outcome between groups. The absolute difference depends on the response rate in the monotherapy group and cannot be determined from the RR alone.

Does the 2026 meta-analysis establish the best combination regimen for vitiligo?

No. It provides comparative evidence for several adjunctive treatments, but differences between studies and uncertainty in some estimates prevent it from establishing a single regimen for all patients.

References

[1] Liu Z, Ng WH, Morriss S, et al. Excimer 308-Nm Light in the Combination Treatment of Vitiligo: A Systematic Review and Network Meta-Analysis. Pigment Cell & Melanoma Research. 2026;39(1). Published online January 21, 2026. doi:10.1111/pcmr.70065.

PubMed: https://pubmed.ncbi.nlm.nih.gov/41564112/